Sotiriou E, Tsentemeidou A, Vakirlis E, et al. - Via this retrospective cross‐sectional analysis, researchers assessed the long‐term efficacy as well as the safety of apremilast in a Greek cohort comprising adult patients suffering from psoriasis who had received at least one dose of apremilast between March 2016 and January 2021. The percentage of patients who achieved 75% decrease in Psoriasis Area Severity Index (PASI75) at Week 16, was the primary endpoint. At several time points, absolute PASI, PASI90 (90% reduction) and adverse events were observed. This analysis involved 102 patients (29.4% women, 70.6% men) with a mean ± SD age 55.94 ± 15.21 years. Overall 20.8% and 1.98% of patients achieved PASI75 and PASI90, respectively, at Week 16. Findings revealed significantly lower PASI90 achievement vs that documented in clinical trials. A gradual increase in apremilast’s efficacy was evident until Week 24, and further improvement was observed in good responders up to Week 52.